从传统和T细胞重定向治疗抗体中划出MYC介导的逃生机制
Anna Vera de Jonge1,2, Tamás Csikós1,2, Merve Eken1,2
1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
International journal of molecular sciences
|November 27, 2024
概括
在B细胞癌中MYC过度表达阻碍了免疫治疗. 抑制MYC通过增强细胞灭绝和T细胞激活来增强自然杀手 (NK) 和T细胞对癌细胞的攻击,从而改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 在B细胞恶性瘤中MYC过度表达与预后不佳相关.
- 对免疫化学疗法的MYC驱动耐药性的机制尚未完全理解.
- 向MYC可能会克服B细胞癌症的治疗抵抗.
研究的目的:
- 调查MYC如何在B细胞恶性瘤中对免疫疗法产生抵抗.
- 探索MYC抑制的潜力,以增强抗体介导的细胞毒性.
主要方法:
- 在淋巴瘤和多发性骨髓瘤细胞系和原发性瘤细胞中药理上抑制MYC.
- 在CRISPR-Cas9基因编辑中,针对OCI-LY18细胞中的MYC基因.
- 评估自然杀手 (NK) 细胞和T细胞介导的细胞毒性,抗原表达,亡途径和T细胞激活.
主要成果:
- 抗MYC抑制增加了对rituximab (抗CD20),daratumumab (抗CD38) 和blinatumomab (抗CD19双特异性T细胞激活剂) 的敏感性.
- 克里斯普尔-卡斯9向MYC调高了CD20,诱导了亡 (调高了PUMA,调低了BCL-2,XIAP,幸存者,MCL-1),并促进了T细胞激活和细胞因子释放.
- 降低MYC调控增强了瘤细胞亡和T细胞反应,表明MYC介导的免疫抑制.
结论:
- 过度表达MYC的B细胞瘤使用多种机制抵抗免疫疗法.
- 调节MYC可以克服免疫逃避并增强基于抗体的免疫疗法的疗效.
- 针对MYC介导的免疫逃避提供了一个有希望的策略,以改善B细胞恶性瘤的结果.
更多相关视频
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
7.9K
09:12Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
811
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Cell-mediated Immune Responses
67.1K
Overview
67.1K
Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
T Cell Activation and Clonal Selection
669
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
669
